![]() |
UMIN-CTR Clinical Trial |
|
![]() |
![]() |
![]() |
![]() |
Name: | UMIN ID: |
Recruitment status | Enrolling by invitation |
Unique ID issued by UMIN | UMIN000048118 |
Receipt No. | R000054834 |
Scientific Title | Joint study on the development of preventive methods for active cardiovascular disease, cerebrovascular disease, and renal disease by vascular endothelial function examination |
Date of disclosure of the study information | 2022/06/23 |
Last modified on | 2022/06/27 |
Basic information | ||
Public title | Arita-cho Vascular Endothelial Function Study | |
Acronym | Arita-cho study | |
Scientific Title | Joint study on the development of preventive methods for active cardiovascular disease, cerebrovascular disease, and renal disease by vascular endothelial function examination | |
Scientific Title:Acronym | Joint study of vascular endothelial function | |
Region |
|
Condition | |||||
Condition | NONE | ||||
Classification by specialty |
|
||||
Classification by malignancy | Others | ||||
Genomic information | NO |
Objectives | |
Narrative objectives1 | In addition to conventional medical examinations, non-invasive vascular endothelial function tests are conducted for the purpose of preventing cardiovascular diseases, cerebrovascular diseases, renal diseases, etc. associated with lifestyle-related diseases, and health examination information and lifestyle information of each inhabitant. And establish health guidance methods, treatment methods, and preventive methods that are suitable for each individual. |
Basic objectives2 | Others |
Basic objectives -Others | Examination of reference values for vascular endothelial function by Endo-PAT test. |
Trial characteristics_1 | |
Trial characteristics_2 | |
Developmental phase |
Assessment | |
Primary outcomes | vascular endothelial function |
Key secondary outcomes | Chiral amino acids |
Base | |
Study type | Observational |
Study design | |
Basic design | |
Randomization | |
Randomization unit | |
Blinding | |
Control | |
Stratification | |
Dynamic allocation | |
Institution consideration | |
Blocking | |
Concealment |
Intervention | |
No. of arms | |
Purpose of intervention | |
Type of intervention | |
Interventions/Control_1 | |
Interventions/Control_2 | |
Interventions/Control_3 | |
Interventions/Control_4 | |
Interventions/Control_5 | |
Interventions/Control_6 | |
Interventions/Control_7 | |
Interventions/Control_8 | |
Interventions/Control_9 | |
Interventions/Control_10 |
Eligibility | ||||
Age-lower limit |
|
|||
Age-upper limit |
|
|||
Gender | Male and Female | |||
Key inclusion criteria | 1. Among the group health examination examinees conducted by Arita Town, those who have obtained informed consent
2. Men and women over 30 years old |
|||
Key exclusion criteria | 1. If your arm tends to swell or bleed
2. When a blood clot can form a blood clot 3. When using antithrombotic agent 4. When the blood clad can cause peripheral circulatory disorders 5. If you are taking other medicines that affect blood vessels 6. When the doctor judges that it is inappropriate due to poor physical condition etc. |
|||
Target sample size | 400 |
Research contact person | |||||||
Name of lead principal investigator |
|
||||||
Organization | Graduate School of Medical Sciences, Kyushu University | ||||||
Division name | Department of Immunoregulatory Cardiovascular Medicine | ||||||
Zip code | 812-8582 | ||||||
Address | 3-1-1, Maidashi, Higashi-ku, Fukuoka City, 812-8582 Japan | ||||||
TEL | 092-642-5360 | ||||||
ide.tomomi.117@m.kyushu-u.ac.jp |
Public contact | |||||||
Name of contact person |
|
||||||
Organization | HuBit genomix,Inc. | ||||||
Division name | Business Department | ||||||
Zip code | 104-0045 | ||||||
Address | 7-10-2 Tukiji,Chuo-ku,Tokyo,104-0045 Japan | ||||||
TEL | 03-5148-3990 | ||||||
Homepage URL | |||||||
mterauchi@hubitgenomix.com |
Sponsor | |
Institute | HuBit genomix,Inc. |
Institute | |
Department |
Funding Source | |
Organization | HuBit genomix,Inc.
TOYO SHINYAKU Co.,Ltd. |
Organization | |
Division | |
Category of Funding Organization | Self funding |
Nationality of Funding Organization |
Other related organizations | |
Co-sponsor | |
Name of secondary funder(s) |
IRB Contact (For public release) | |
Organization | HuBit genomix,Inc. |
Address | 7-10-2 Tukiji,Chuo-ku,Tokyo,104-0045 Japan |
Tel | 0351483990 |
mterauchi@hubitgenomix.com |
Secondary IDs | |
Secondary IDs | NO |
Study ID_1 | |
Org. issuing International ID_1 | |
Study ID_2 | |
Org. issuing International ID_2 | |
IND to MHLW |
Institutions | |
Institutions |
Other administrative information | |||||||
Date of disclosure of the study information |
|
Related information | |
URL releasing protocol | |
Publication of results | Unpublished |
Result | |
URL related to results and publications | |
Number of participants that the trial has enrolled | |
Results | |
Results date posted | |
Results Delayed | |
Results Delay Reason | |
Date of the first journal publication of results | |
Baseline Characteristics | |
Participant flow | |
Adverse events | |
Outcome measures | |
Plan to share IPD | |
IPD sharing Plan description |
Progress | |||||||
Recruitment status | Enrolling by invitation | ||||||
Date of protocol fixation |
|
||||||
Date of IRB |
|
||||||
Anticipated trial start date |
|
||||||
Last follow-up date |
|
||||||
Date of closure to data entry | |||||||
Date trial data considered complete | |||||||
Date analysis concluded |
Other | |
Other related information | Cohort study
The vascular endothelial function is measured by the Endo-PAT test, and the reference value is obtained. Evaluate the relationship with clinical laboratory test values and chiral amino acids obtained in medical examinations. |
Management information | |||||||
Registered date |
|
||||||
Last modified on |
|
Link to view the page | |
URL(English) | https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000054834 |
Research Plan | |
Registered date | File name |
Research case data specifications | |
Registered date | File name |
Research case data | |
Registered date | File name |